Literature DB >> 2584217

Heparin-modulated binding of pancreatic lipase and uptake of hydrolyzed triglycerides in the intestine.

M S Bosner1, T Gulick, D J Riley, C A Spilburg, L G Lange.   

Abstract

Utilizing small intestine membranes that contain heparin (50 micrograms/mg protein), binding of triglyceride lipase (homogeneous 52 kDa, specific activity, 70 nmol/mg.h) to membranes was shown to be concentration dependent and saturable, and it was characterized by a single dissociation constant (KD = 86 +/- 16 nM) with a maximal binding capacity of 54 +/- 8 pmol/mg of vesicle protein. Specific binding was decreased in a concentration-dependent manner by the addition of exogenous heparin, and binding was virtually eliminated (less than 6% control values) by pretreatment of membranes with bacterial heparinase. Cultured intestinal epithelial cells (CaCo-2), shown to possess membrane-associated heparin, also bound pancreatic triglyceride lipase in a specific and saturable manner, with KD = 77 +/- 12 nM and Bmax = 13.7 +/- 6 pmol/10(6) cells. Soluble heparin not only decreased binding, but it also diminished the enzyme-mediated cellular uptake of [14C]oleate from [14C]triolein by over 75%. Therefore, intestinal heparin, a component of the brush border membrane, localizes pancreatic triglyceride lipase in a receptor-like manner to the plasma membrane to promote the subsequent absorption of fatty acids derived from hydrolyzed triglycerides.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584217

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  2 in total

1.  Secreted intestinal surfactant-like particles interact with cell membranes and extracellular matrix proteins in rats.

Authors:  Akhtar Mahmood; Michael J Engle; David H Alpers
Journal:  J Physiol       Date:  2002-07-01       Impact factor: 5.182

2.  Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug.

Authors:  Sifei Han; Luojuan Hu; Tim Quach; Jamie S Simpson; Natalie L Trevaskis; Christopher J H Porter
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.